European Pharmaceutical Manufacturer editor Reece Armstrong looks at the antibiotics landscape and why we need to speak up about antimicrobial resistance (AMR).
In April this year, as the Covid-19 pandemic continued to dominate headlines across global media channels, the World Health Organisation (WHO) published its latest annual review evaluating the current clinical and preclinical pipelines for antibacterial candidates.
Conclusions from the report were stark, with WHO assistant director general on antimicrobial resistance (AMR), Dr Hanan Balkhy, saying that AMR is being fuelled by “the persistent failure to develop, manufacture, and distribute effective new antibiotics.”